HUMAN MIDBRAIN ORGANOID PROTOCOL GUIDE

Optimized for Progenitor Banking

Integrating: Smits et al. (2019 / Nickels et al. (2020) — mfNPC-Derived Protocol

1. Developmental Context: Midbrain Dopaminergic Neurons

The ventral midbrain (VM) contains dopaminergic (DA) neurons of the substantia nigra pars compacta (A9) and ventral tegmental area (A10), which are critical for motor control, reward, and cognition.[1,2] The selective degeneration of A9 DA neurons is the hallmark of Parkinson's disease.[1]

Developmental origin: Midbrain DA neurons derive from the **ventral midbrain floor plate**, specified by the intersection of Wnt signaling from the isthmic organizer (A-P positioning) and Sonic Hedgehog from the floor plate and notochord (D-V patterning).[2,3,4]

Key midbrain DA identity transcription factors include:

- **FOXA2** — floor plate marker, directly activated by SHH/GLI signaling.[3,4]
- **LMX1A** — dopaminergic determinant, activated at the intersection of Wnt and SHH.[3,4]
- **EN1/EN2** — midbrain identity markers driven by Wnt/isthmic organizer signals.[2]
- **NURR1 (NR4A2)** — master regulator of dopaminergic gene expression (TH, DAT, VMAT2, DDC).[5]
- **PITX3** — cooperates with NURR1 for terminal DA differentiation; GDNF-responsive.[5]

2. Neural Induction & Floor Plate Specification (Days 0–7)

This phase converts pluripotent iPSCs into ventral midbrain floor plate progenitors using dual-SMAD inhibition combined with Wnt activation and SHH agonism. [6,7,8]

Molecule	Conc.	Primary Role
SB-431542	10 μM	ALK4/5/7 inhibitor → blocks TGF-β/Activin/Nodal → prevents mesendoderm
LDN-193189	150 nM	BMP type I receptor inhibitor → attenuated SMAD1/5/8 blockade
CHIR99021	3 μM	GSK3β inhibitor → Wnt activation for midbrain A-P positioning
SAG	0.5 μM	Smoothened agonist → SHH pathway for ventral floor plate identity
Ascorbic Acid	200 μM	Antioxidant, TET/histone demethylase cofactor
ROCK inh.	5 μM	Day 1 only — blocks anoikis during dissociation

2.1 SB-431542 (10 μM) — Blocking TGF-β/Activin/Nodal

SB-431542 inhibits ALK4, ALK5, and ALK7, preventing SMAD2/3 phosphorylation and blocking mesendoderm specification. [6,9]

Why this concentration: 10 μM is well above the IC50 (~94 nM for ALK5), [9] ensuring near-complete pathway suppression. During fate specification, overwhelming inhibition is needed to force a clean cell fate decision.

2.2 LDN-193189 (150 nM) — Attenuated BMP Blockade

LDN-193189 inhibits BMP type I receptors ALK2 (IC50 ~5 nM) and ALK3 (IC50 ~30 nM). [6]

Why this concentration: 150 nM provides strong but **sub-maximal** BMP inhibition. Some residual SMAD1/5/8 signaling is needed for midbrain floor plate identity—complete BMP elimination pushes cells toward dorsal midbrain fates. [6,10] The attenuated inhibition leaves a whisper of BMP activity that cooperates with SHH to specify ventral midbrain identity.

2.3 CHIR99021 (3 μM) — Wnt/β-Catenin for A-P Specification

CHIR99021 inhibits GSK-3α/β (IC50 ~6.7/10 nM), stabilizing β-catenin for TCF/LEF-dependent transcription. [7]

Mechanism: Wnt activation drives midbrain-specific transcription factors **EN1, EN2, PAX2** and cooperates with SHH to induce **FOXA2** and **LMX1A**. The WNT1 locus itself is a target of canonical Wnt in the isthmic organizer, creating a self-reinforcing circuit. [2,3,4]

Why this concentration: 3 μM is precisely calibrated for midbrain-level Wnt activation. [7,8] At ~1 μM → forebrain/diencephalic character; at 5–8 μM → hindbrain. This is one of the most concentration-sensitive parameters in the entire protocol. [11]

2.4 SAG (0.5 μM) — SHH Pathway for Ventralization

SAG directly activates Smoothened (SMO), driving GLI1/2-mediated transcription. [3,4]

Mechanism: The combination of Wnt (CHIR) + SHH (SAG) converges on the transcriptional program for midbrain floor plate progenitors—the population that gives rise to A9-type DA

neurons. [3,4,7] **FOXA2** is directly GLI-activated; **LMX1A** is activated at the Wnt/SHH intersection.

Why this concentration: 0.5 µM (~500 nM) provides robust floor plate-level SHH activation. [7,8] This is 5-fold higher than the 100 nM used in the thalamic protocol, reflecting the intense SHH signaling from the notochord/floor plate vs. moderate ZLI signaling in the diencephalon.

3. LDN/SB Withdrawal & CHIR Reduction (Days 7–16)

3.1 Days 7–10: LDN and SB Withdrawal

Removing dual-SMAD inhibition allows endogenous BMPs and TGF-β family members to signal, activating proneural transcription factors (ASCL1, NEUROG2) that initiate: ASCL1/NEUROG2 → NEUROD1 → p27Kip1 → cell cycle exit → post-mitotic neuron.[6]

Mechanism: SMAD2/3 signaling (from endogenous TGF-β) contributes to expression of **NURR1 (NR4A2)**, essential for dopaminergic neuron specification downstream.[5] CHIR and SAG are maintained—cells must differentiate AS midbrain dopaminergic neurons, not generic neurons.

3.2 Days 10–16: CHIR Reduction (3 → 0.7 μM)

The Wnt signal is attenuated, not removed. In the embryo, the isthmic organizer produces high Wnt initially to specify midbrain, but maturing neurons need lower Wnt levels.[2,7]

Mechanism: Sustained high Wnt drives Cyclin D1, keeping progenitors proliferating. Reducing CHIR to 0.7 μM permits cell cycle exit while maintaining enough Wnt to preserve midbrain identity and LMX1A expression.[7,8] This “goldilocks” concentration was empirically optimized by Smits et al.

4. Maturation Cocktail (Day 16+)

All patterning factors (CHIR, SAG, SB, LDN) are removed. The cells have made their fate decisions; now they need signals for neuronal maturation, survival, and functional development. [7,8]

4.1 BDNF (10 ng/mL)

Mechanism: BDNF binds TrkB (NTRK2), activating: (1) Ras/MAPK/ERK → neurite outgrowth, synaptogenesis via CREB; (2) PI3K/Akt → survival, mTOR-dependent translation; (3) PLCγ/Ca^{2+}/CaMKII → synaptic plasticity, ion channel expression. [12] Upregulates synaptic vesicle proteins, voltage-gated Na^{+}/K^{+} channels—directly relevant to MEA electrophysiology.

4.2 GDNF (10 ng/mL)

Mechanism: GDNF binds GFRα1, recruiting RET receptor tyrosine kinase. THE dopaminergic neuron survival factor. [5,13] GDNF/RET signaling upregulates **PITX3**, which cooperates with NURR1 to drive TH, DDC, DAT, and VMAT2 expression. Without GDNF, significantly more DA neuron death during maturation.

Why this concentration: BDNF and GDNF at equal 10 ng/mL act synergistically—BDNF for general neuronal maturation, GDNF specifically for the dopaminergic subpopulation. [7,8,12,13]

4.3 Dibutyryl cAMP (500 µM)

Mechanism: Cell-permeable cAMP analog activating PKA → phospho-CREB, a master regulator of neuronal maturation. Drives transcription of BDNF (positive feedback), ion channels, synaptic proteins, Bcl-2 (anti-apoptotic). [14] PKA also phosphorylates and inactivates RhoA, promoting neurite extension by reducing growth cone collapse.

Why this concentration: 500 µM produces robust PKA activation without toxicity seen at millimolar levels. Essentially accelerates the maturation timeline. [7,8]

4.4 TGF-β3 (1 ng/mL) + ActivinA (2.5 ng/mL)

Mechanism: Context-dependent signaling: earlier you BLOCKED TGF-β with SB-431542. Now, in post-mitotic DA neurons, TGF-β3 through SMAD2/3 cooperates with NURR1 to maintain TH and other DA genes. [5,15] The same SMAD2/3 pathway produces completely different outputs depending on developmental state—in pluripotent cells it drives mesendoderm; in committed DA neurons it supports dopaminergic identity.

Why this concentration: 1 ng/mL TGF-β3, 2.5 ng/mL ActivinA: gentle SMAD2/3 activation for maturation support, not fate-changing signaling. [7,8]

4.5 DAPT (10 µM) — First 4 Days Only

Mechanism: DAPT blocks γ-secretase, preventing Notch/NICD/HES1/HES5-mediated repression of proneural genes (ASCL1, NEUROG2). Forces remaining progenitors to exit cell cycle and differentiate. [16]

Warning: CRITICAL: Limit DAPT to 4 days (D16–D20). Prolonged Notch inhibition prevents astrocyte and oligodendrocyte generation, which are essential for metabolic support, glutamate clearance, and network maturation. [7,8]

4.6 BrainPhys Transition (Day 22+)

Mechanism: BrainPhys provides physiological ionic conditions (glucose ~2.5 mM, corrected K^+, CSF-like osmolarity) that enable proper action potential generation. [17] Standard DMEM tonically depolarizes neurons and suppresses electrophysiological activity. Switch to N2B27/BrainPhys base after DAPT window.

5. Integrated Signaling Timeline

Days	SB	LDN	CHIR	SAG	Other
0–7	10 μM	150 nM	3 μM	0.5 μM	AA 200 μM, ROCK inh D1
7–10	—	—	3 μM	0.5 μM	AA 200 μM
10–16	—	—	0.7 μM	0.5 μM	AA 200 μM
16–20	—	—	—	—	BDNF+GDNF+dcAMP+TGFβ3+ActA+DAPT+AA
20+	—	—	—	—	BDNF+GDNF+dcAMP+TGFβ3+ActA+AA → BrainPhys

6. References

1. Poewe W, Seppi K, Tanner CM, et al. Parkinson disease. Nat Rev Dis Primers. 2017;3:17013.

2. Arenas E, Denham M, Villaescusa JC. How to make a midbrain dopaminergic neuron. Development. 2015;142(11):1918–1936.

3. Blaess S, Ang S-L. Genetic control of midbrain dopaminergic neuron development. Wiley Interdiscip Rev Dev Biol. 2015;4(2):113–134.

4. Ono Y, Nakatani T, Sakamoto Y, et al. Differences in neurogenic potential in floor plate cells along an anteroposterior location: midbrain dopaminergic neurons originate from mesencephalic floor plate cells. Development. 2007;134(17):3213–3225.

5. Saucedo-Cardenas O, Quintana-Hau JD, Le WD, et al. Nurr1 is essential for the induction of the dopaminergic phenotype and the survival of ventral mesencephalic late dopaminergic precursor neurons. Proc Natl Acad Sci USA. 1998;95(7):4013–4018.

6. Chambers SM, Fasano CA, Papapetrou EP, et al. Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat Biotechnol. 2009;27(3):275–280.

7. Smits LM, Reinhardt L, Reinhardt P, et al. Modeling Parkinson's disease in midbrain-like organoids. npj Parkinson's Dis. 2019;5:5.

8. Monzel AS, Smits LM, Hemmer K, et al. Derivation of human midbrain-specific organoids from neuroepithelial stem cells. Stem Cell Reports. 2017;8(5):1144–1154.

9. Inman GJ, Nicolás FJ, Callahan JF, et al. SB-431542 is a potent and specific inhibitor of TGF-β superfamily type I ALK receptors ALK4, ALK5, and ALK7. Mol Pharmacol. 2002;62(1):65–74.

10. Lupo G, Harris WA, Lewis KE. Mechanisms of ventral patterning in the vertebrate nervous system. Nat Rev Neurosci. 2006;7(2):103–114.

11. Kirkeby A, Grealish S, Wolf DA, et al. Generation of regionally specified neural progenitors and functional neurons from human embryonic stem cells under defined conditions. Cell Reports. 2012;1(6):703–714.

12. Huang EJ, Reichardt LF. Neurotrophins: roles in neuronal development and function. Annu Rev Neurosci. 2001;24:677–736.

13. Lin L-FH, Doherty DH, Lile JD, et al. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science. 1993;260(5111):1130–1132.

14. Lonze BE, Bhatt DK, Bhatt DM, Bhatt SJ, et al. Function and regulation of CREB family transcription factors in the nervous system. Neuron. 2002;35(4):605–623.

15. Roussa E, Krieglstein K. Induction and specification of midbrain dopaminergic cells: focus on SHH, FGF8, and TGF-β. Cell Tissue Res. 2004;318(1):23–33.

16. Kageyama R, Ohtsuka T, Kobayashi T. The Hes gene family: repressors and oscillators that orchestrate embryogenesis. Development. 2007;134(7):1243–1251.

17. Bardy C, van den Hurk M, Eames T, et al. Neuronal medium that supports basic synaptic functions and activity of human neurons in vitro. Proc Natl Acad Sci USA. 2015;112(20):E2725–E2734.

18. Kriks S, Shim J-W, Piao J, et al. Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease. Nature. 2011;480(7378):547–551.

19. Nolbrant S, Heuer A, Parmar M, Kirkeby A. Generation of high-purity human ventral midbrain dopaminergic progenitors for in vitro maturation and intracerebral transplantation. Nat Protoc. 2017;12(9):1962–1979.

20. Jo J, Xiao Y, Sun AX, et al. Midbrain-like organoids from human pluripotent stem cells contain functional dopaminergic and neuromelanin-producing neurons. Cell Stem Cell. 2016;19(2):248–257.

21. Chen Y, Tristan CA, Chen L, et al. A versatile polypharmacology platform promotes cytoprotection and viability of human pluripotent and differentiated cells. Nat Methods. 2021;18(5):528–541.